- Home
- LGND vs IMVT Comparison
LGND vs IMVT Comparison
Compare LGND & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGND
- IMVT
- Stock Information
- Founded
- LGND 1987
- IMVT 2018
- Country
- LGND United States
- IMVT United States
- Employees
- LGND 68
- IMVT N/A
- Industry
- LGND Biotechnology: Pharmaceutical Preparations
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGND Health Care
- IMVT Health Care
- Exchange
- LGND Nasdaq
- IMVT Nasdaq
- Market Cap
- LGND 3.2B
- IMVT 2.7B
- IPO Year
- LGND 1992
- IMVT N/A
- Fundamental
- Price
- LGND $205.69
- IMVT $23.75
- Analyst Decision
- LGND Strong Buy
- IMVT Buy
- Analyst Count
- LGND 8
- IMVT 9
- Target Price
- LGND $144.71
- IMVT $27.71
- AVG Volume (30 Days)
- LGND 139.7K
- IMVT 1.7M
- Earning Date
- LGND 08-05-2025
- IMVT 11-10-2025
- Dividend Yield
- LGND N/A
- IMVT N/A
- EPS Growth
- LGND N/A
- IMVT N/A
- EPS
- LGND N/A
- IMVT N/A
- Revenue
- LGND $181,488,000.00
- IMVT N/A
- Revenue This Year
- LGND $18.41
- IMVT N/A
- Revenue Next Year
- LGND $18.87
- IMVT N/A
- P/E Ratio
- LGND N/A
- IMVT N/A
- Revenue Growth
- LGND 53.40
- IMVT N/A
- 52 Week Low
- LGND $81.74
- IMVT $12.72
- 52 Week High
- LGND $129.90
- IMVT $29.49
- Technical
- Relative Strength Index (RSI)
- LGND 59.63
- IMVT 60.56
- Support Level
- LGND $198.82
- IMVT $21.86
- Resistance Level
- LGND $209.10
- IMVT $24.07
- Average True Range (ATR)
- LGND 7.14
- IMVT 1.29
- MACD
- LGND -0.67
- IMVT -0.22
- Stochastic Oscillator
- LGND 53.60
- IMVT 68.53
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.